Claims for Patent: 5,599,323

Summary for Patent: 5,599,323

Title:	Syringe system
Abstract:	An insulin injection system comprises a pen shaped syringe with a cartridge containing insulin, and an injection needle. The needle is a G30 needle and the insulin is a type which may freely flow through a G 30 needle. When the insulin is the type comprising suspended crystals the maximal dimension of any crystal is 15 .mu.m.
Inventor(s):	Bonnichsen; Frits F. (Lynge, DK), J.o slashed.rgensen; Peter N. (Broenshoej, DK)
Assignee:	Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:	08/550,494
Patent Claims:	1. A needle assembly comprising: (a) a needle hub having a base and a standard insulin needle fitting for removably mounting said needle assembly on a pen-type insulin syringe having a standard mounting and which accepts cartridges containing only insulin types that may flow freely through a G30 needle; and (b) a G30 needle secured in said base and having first and second needle portions extending from said base in opposite directions. 2. A needle assembly according to claim 1, wherein said standard fitting includes an annular sleeve extending from said base such that said sleeve surrounds said first needle portion concentrically and is spaced therefrom, and wherein said sleeve has a threaded interior by which it may be screwed onto a standard, externally threaded, hub-receiving part of a pen-type insulin syringe. 3. A needle assembly according to claim 2, and wherein said second needle portion has a predetermined length appropriate for injecting insulin into a human patient. 4. A needle assembly according to claim 3, wherein said base further comprises a central protrusion which extends from said base for a predetermined distance along said second needle portion and embeds said second needle portion along the said distance, and wherein said second needle portion further comprises an exposed end which projects axially from said central protrusion and which has a length corresponding to the desired depth of needle insertion into a human patient.

Details for Patent 5,599,323

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	October 28, 1982		2015-10-30
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	December 29, 2015		2015-10-30
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	August 06, 1998		2015-10-30
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	March 31, 1994		2015-10-30
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	May 25, 2018		2015-10-30
Baxter Healthcare Corporation	MYXREDLIN	insulin human	Injection	208157	June 20, 2019		2015-10-30